

University of Groningen

Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening

van Eupen, Marcelle G. A.; Schram, Miranda T.; van Sloten, Thomas T.; Scheijen, Jean; Sep, Simone J. S.; van der Kallen, Carla J.; Dagnelie, Pieter C.; Koster, Annemarie; Schaper, Nicolaas; Henry, Ronald M. A.

Published in:
Hypertension

DOI:
[10.1161/HYPERTENSIONAHA.116.07446](https://doi.org/10.1161/HYPERTENSIONAHA.116.07446)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Eupen, M. G. A., Schram, M. T., van Sloten, T. T., Scheijen, J., Sep, S. J. S., van der Kallen, C. J., Dagnelie, P. C., Koster, A., Schaper, N., Henry, R. M. A., Kroon, A. A., Smit, A. J., Stehouwer, C. D. A., & Schalkwijk, C. G. (2016). Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study. *Hypertension*, 68(4), 956-963. <https://doi.org/10.1161/HYPERTENSIONAHA.116.07446>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening The Maastricht Study

Marcelle G.A. van Eupen, Miranda T. Schram, Thomas T. van Sloten, Jean Scheijen, Simone J.S. Sep, Carla J. van der Kallen, Pieter C. Dagnelie, Annemarie Koster, Nicolaas Schaper, Ronald M.A. Henry, Abraham A. Kroon, Andries J. Smit, Coen D.A. Stehouwer, Casper G. Schalkwijk

Abstract—Arterial stiffening, as characterized by an increase in carotid–femoral pulse-wave velocity or pulse pressure, increases the risk of cardiovascular disease, especially among individuals with type 2 diabetes mellitus. Advanced glycation end products are hypothesized to play a role in the development of arterial stiffness. Therefore, we investigated the association between skin autofluorescence, an estimate of tissue advanced glycation end products, and plasma advanced glycation end products on the one hand and arterial stiffening on the other in 862 participants of The Maastricht Study (mean age of 60 years; 45% women) with normal glucose metabolism ($n=469$), impaired glucose metabolism ($n=140$), or type 2 diabetes ($n=253$). Associations were analyzed with linear regression analysis and adjusted for potential confounders. We found that higher skin autofluorescence as measured by the AGE Reader and plasma pentosidine were independently associated with higher carotid–femoral pulse-wave velocity (β 0.10; 95% confidence interval, 0.03–0.17 and 0.10; 0.04–0.16, respectively) and central pulse pressure (β 0.08; 95% confidence interval 0.01–0.15 and 0.07; 0.01–0.13, respectively). The associations between skin autofluorescence and pentosidine, and carotid–femoral pulse-wave velocity were more pronounced in individuals with type 2 diabetes mellitus (P -interaction <0.10). These results support the hypothesis that accumulation of advanced glycation end products is involved in arterial stiffening and may explain part of the increased risk of cardiovascular disease in individuals with type 2 diabetes mellitus. (*Hypertension*. 2016;68:956–963. DOI: 10.1161/HYPERTENSIONAHA.116.07446.) • [Online Data Supplement](#)

Key Words: advanced glycation end products ■ arterial stiffness ■ autofluorescence imaging ■ blood pressure ■ diabetes mellitus, type 2 ■ pentosidine

Arterial stiffening, a measure of subclinical arterial injury, is associated with cardiovascular disease (CVD) and mortality^{1–4} in a variety of populations, including in type 2 diabetes mellitus (T2DM).⁵ Moreover, the age-related increase in arterial stiffness is steeper in individuals with T2DM compared with individuals without.^{6,7} The exact mechanisms behind the development of arterial stiffness and subsequent CVD are not completely understood. The increased accumulation of advanced glycation end products (AGEs) on long-lived proteins, such as collagen in the arterial wall, may lead to the formation of cross links, and in the arterial wall, may subsequently lead to increased stiffening.⁸ Additionally, AGEs have been linked to arterial stiffness via other mechanisms like intracellular protein glycation or receptor for AGE (RAGE)

activation.⁹ AGEs are thus thought to play a crucial role in the development of arterial stiffness, especially in T2DM.

Indeed, several studies found an association between measures of AGE accumulation and arterial stiffening.^{10–20} Only one case–control study investigated this association in individuals with T2DM. This study found no association between serum pentosidine and heart-brachial pulse-wave velocity or brachial-ankle pulse-wave velocity after adjustment for renal function.¹⁵ However, it did not take other potential confounders into account. Moreover, the measurement of skin autofluorescence (SAF) has recently emerged as an estimate of AGE accumulation in skin tissue²¹ and may thereby be a better estimate of tissue AGE accumulation than plasma AGEs. To date, no study has investigated the association between SAF and plasma AGEs and

Received March 16, 2016; first decision July 20, 2016; revision accepted July 20, 2016.

From the Department of Internal Medicine (M.G.A.v.E., M.T.S., T.T.v.S., J.S., S.J.S.S., C.J.v.d.K., N.S., R.M.A.H., A.A.K., C.D.A.S., C.G.S.); Department of Epidemiology (P.C.D.); Department of Social Medicine (A.K.); Cardiovascular Research Institute Maastricht (CARIM) (M.G.A.v.E., M.T.S., T.T.v.S., J.S., S.J.S.S., C.J.v.d.K., P.C.D., N.S., R.M.A.H., A.A.K., C.D.A.S., C.G.S.); School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, The Netherlands (P.C.D., A.K., N.S., C.D.A.S.); and Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, University of Groningen, The Netherlands (A.J.S.).

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.116.07446/-DC1>.

Correspondence to Casper G. Schalkwijk, Maastricht University Medical Center, Department of Internal Medicine, Universiteitssingel 50, 6200 MD, Maastricht, the Netherlands. E-mail c.schalkwijk@maastrichtuniversity.nl

© 2016 American Heart Association, Inc.

Hypertension is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.116.07446

carotid to femoral pulse-wave velocity (cfPWV) or pulse pressure, both measures of aortic stiffening, in a population-based setting, including individuals with normal glucose metabolism (NGM), impaired glucose metabolism (IGM), and T2DM.

In view of these considerations, the aims of our study were, first, to evaluate the independent association between SAF and plasma AGEs on the one hand and measures of arterial stiffening, ie, cfPWV, central pulse pressure, and 24-hour ambulatory pulse pressure, on the other. Second, to examine whether these associations differed between individuals with NGM, IGM, or T2DM.

Methods

Study Population and Design

In this study, we used data from The Maastricht Study, an observational prospective population-based cohort study. The rationale and methodology have been described previously.²² In brief, the study focuses on the cause, pathophysiology, complications, and comorbidities of type 2 diabetes mellitus (T2DM) and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known T2DM status for reasons of efficiency. The present report includes cross-sectional data from the first 866 participants, who completed the baseline survey between November 2010 and March 2012. The examinations of each participant were performed within a time window of 3 months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Netherlands Health Council under the Dutch “Law for Population Studies” (Permit 131088-105234-PG). All participants gave written informed consent. From the initial 866 individuals included in this study, we excluded individuals with type 1 diabetes mellitus (n=4).

Skin Autofluorescence

All participants were asked to refrain from smoking and caffeine at least 3 hours before the measurements. A light meal (breakfast or lunch), low in fat content, was allowed. SAF was measured with the AGE Reader (DiagnOptics Technologies BV, Groningen, The Netherlands). The AGE reader is a desktop device that uses the characteristic fluorescent properties of certain AGEs to estimate the level of AGE accumulation in the skin. Technical details of this noninvasive method have been described more extensively elsewhere.²¹ In short, the AGE Reader illuminates a skin surface of 4 cm² guarded against surrounding light, with an excitation wavelength range of 300 to 420 nm, with a peak excitation of 370 nm. SAF was calculated as the ratio between the emission light from the skin in the wavelength range of 420 to 600 nm (fluorescence) and excitation light that is reflected by the skin (300–420 nm), multiplied by 100 and expressed in arbitrary units. Participants were asked not to use any sunscreen or self-browning creams on their lower arms within 2 days before the measurement. SAF was measured at room temperature in a semi-dark environment, whereas participants were at rest in a seated position. The inner side of the forearm ≈4 cm below the elbow fold of a participant was positioned on top of the device, as described by the manufacturer. The mean of 3 consecutive measurements was used in the analyses. Reproducibility was assessed in 14 individuals without diabetes mellitus (6 men; 32.2±7.1 years). The intraclass correlation coefficient of 3 intraindividual consecutive SAF measurements was 0.83 (95% confidence interval [CI], 0.65–0.94). SAF was calculated offline by automated analysis using AGE Reader software, version 2.3, and was observer independent. There were no significant differences between fasting and nonfasting measurements (mean difference=0.01 arbitrary units; *P*=0.73). Reproducibility in individuals with T2DM has been evaluated previously²¹ with an overall Altman error percentage of 5.03% for measurements taken over a single day.

Skin pigmentation is known to influence the measurement of SAF.²³ Therefore, in participants with dark-colored skin with a reflectance of 6% to 10%, a validated reflectance-dependent correction was made by the software.²³ Measurements in participants with dark-colored skin and a mean reflectance below 6% are considered unreliable and are therefore not used to calculate SAF by the software. Therefore, these participants were automatically excluded (n=1). Additionally, a single SAF value above 10 arbitrary units was considered as unreliable; these individual measurements (n=3) were manually excluded, and the mean of the remaining 2 measurements was used in analyses.

Analysis of Protein-Bound AGEs and Lysine in Plasma

Plasma AGEs were measured in EDTA samples obtained from fasting venous blood, which were stored at –80 °C until analysis. Protein-bound pentosidine was quantified using high-performance liquid chromatography with fluorescence detection, as described in detail elsewhere.²⁴ Intra- and interassay coefficients of variation, as analyzed in this study, were 6.5% and 7.8% for pentosidine, respectively. Protein-bound Nε-(carboxymethyl)lysine (CML) and Nε-(carboxyethyl)lysine (CEL) and lysine were quantified using ultra-performance liquid chromatography tandem mass-spectrometry.²⁵ Intra- and interassay coefficients of variation were 4.5% and 6.7% for CML, 6.2% and 10.3% for CEL, and 5.0% and 5.3% for lysine. Concentrations of protein-bound pentosidine, CML, and CEL were adjusted for levels of lysine and expressed as nmol/mmol lysine.

Carotid to Femoral Pulse-Wave Velocity and Central Pulse Pressure

As described previously,²⁶ cfPWV and central pulse pressure (cPP) were assessed noninvasively by means of applanation tonometry. All measurements (≈45 minutes) were done by trained vascular technicians unaware of the participants' clinical or diabetes mellitus status. Measurements took place in a quiet, temperature-controlled room (21–23°C) and were performed in supine position, after 10 minutes of rest. Participants were asked to refrain from smoking and drinking coffee or tea or alcohol beverages 3 hours before the study. Participants were allowed to have a light meal (breakfast and lunch). Talking or sleeping was not allowed during the examination. A 3-lead ECG was recorded continuously during the measurements to facilitate automatic signal processing. In addition, brachial systolic, diastolic, and mean arterial pressure were determined repeatedly with a 5-minute interval, using an oscillometric device (Accutorr Plus, Datascope, Inc, Montvale, NJ), and the average of these measurements was calculated. cfPWV was determined according to recent guidelines²⁷ with the use of applanation tonometry (SphygmoCor, Atcor Medical, Sydney, Australia). Pressure waveforms were determined at the right common carotid and right common femoral arteries. The difference in the time of pulse arrival from the R-wave of the ECG between the 2 sites (transit time) was determined with the intersecting tangents algorithm. The pulse wave travel distance was calculated as 80% of the direct straight distance (measured with an infantometer) between the 2 arterial sites. cfPWV was defined as travelled distance/transit time. cPP was determined by radial applanation tonometry (Sphygmocor, Atcor Medical, Australia).²⁸ The median of 3 consecutive cfPWV and cPP recordings were used in the analyses.

Glucose Metabolism Status

As described previously,²² to determine glucose metabolism, all participants (except those who used insulin) underwent a standardized 7-point oral glucose tolerance test after an overnight fast. Blood samples were taken at baseline and at 15, 30, 45, 60, 90, and 120 minutes after ingestion of a 75 g glucose drink. For safety reasons, participants with a fasting glucose level above 11.0 mmol/L, as determined by a finger prick, did not undergo the oral glucose tolerance test. For these individuals (n=13), fasting glucose level and information about diabetes mellitus medication use were used to determine glucose metabolism status. Glucose metabolism was defined according to the WHO 2006 criteria into normal glucose tolerance, impaired fasting

glucose, impaired glucose tolerance, and T2DM.²⁹ For this study, we defined having either impaired fasting glucose or impaired glucose tolerance as IGM.

For method description on 24-hour ambulatory blood pressure, peripheral neuropathy, diabetic nephropathy, and other covariates, we refer to the [online-only Data Supplement](#).

Statistical Methods

Analyses were conducted using SPSS version 21 for Windows. Comparisons of baseline characteristics between groups were made by use of ANOVA or χ^2 tests. Variables with a skewed distribution were \log_{10} transformed before analysis. We used standardized multiple linear regression analysis to evaluate the association between SAF and plasma AGEs on the one hand and cfPWV, cPP, and 24-hour ambulatory pulse pressure (aPP) on the other, which enabled us to adjust for possible confounding factors. As presented in each table, we included all available data in the analyses to avoid selection bias. We investigated whether or not these associations differed between individuals with different glucose metabolism status by adding interaction terms in our models (eg, the product of (1) SAF or plasma AGE levels and (2) glucose metabolism status). *P* values <0.05 were considered statistically significant, except for interaction terms, where a *P* value <0.10 was considered statistically significant.

Results

General Characteristics

Table 1 shows the general characteristics, stratified according to tertiles of cfPWV. Data on SAF were available in 831 individuals, plasma AGEs in 843, cfPWV data in 820, and cPP data in 828 individuals. Missing data were predominantly caused by device nonavailability or technical problems. Plasma AGEs were measured in blood samples, which, for the missing cases, were mostly not available because of difficulties in blood withdrawal. As a sensitivity analysis, we additionally performed all analyses in a data set where missing values were imputed by multiple imputation using SPSS. These additional analyses were not materially different from our original analyses. The percentage of individuals with IGM or T2DM, peripheral sensory neuropathy, albuminuria, hypertension, antihypertensive or lipid-modifying or diabetes medication, and a history of CVD was higher in the higher cfPWV tertiles. Also, with higher cfPWV tertile, the percentage of men and former smokers was higher, as were age, diabetes mellitus duration, glycohemoglobin, waist circumference, total-to-high-density lipoprotein cholesterol ratio and triglycerides; eGFR was lower with higher cfPWV. SAF and plasma pentosidine level were higher with higher cfPWV, as were mean arterial pressure and heart rate (Table 1). For the general characteristics stratified by glucose metabolism status, please see Table S1 in the [online-only Data Supplement](#).

Associations Between AGE Accumulation and Aortic Stiffening

Both SAF ($s\beta$ 0.09; 95% CI, 0.03–0.16) and plasma pentosidine ($s\beta$ 0.09; 95% CI, 0.03–0.16) were significantly associated with higher cfPWV, after adjustment for age, sex, glucose metabolism status, average mean arterial pressure, and heart rate obtained during cfPWV measurement; waist circumference; smoking; antihypertensive, lipid-modifying, and diabetes mellitus medication use; eGFR; total-to-high-density lipoprotein cholesterol ratio; triglycerides; and a history of cardiovascular disease (Table 2). These associations were

more pronounced in individuals with T2DM (SAF: $s\beta$ 0.13; 95% CI, –0.01 to 0.28; pentosidine: $s\beta$ 0.12; 95% CI, –0.02 to 0.26, *P* values for interaction <0.10) (Figure). The association between SAF and cfPWV was also more pronounced in individuals with IGM compared to those with NGM ($s\beta$ 0.13, 95%–CI –0.05 to 0.31), but without significant interaction (*P*=0.322; Figure). SAF ($s\beta$ 0.08; 95% CI, 0.01–0.15) and plasma pentosidine ($s\beta$ 0.07; 95% CI, 0.01–0.13) showed positive and similar significant associations with cPP after adjustment for age, sex, glucose metabolism status, average 24-hour mean arterial pressure, average 24-hour heart rate, waist circumference, smoking, antihypertensive or lipid-modifying or diabetes medication use, eGFR, total-to-high-density lipoprotein cholesterol ratio, triglycerides, and a history of cardiovascular disease (Table 2). The associations between SAF and AGEs on the one hand and cPP on the other were not different for different glucose metabolism status (*P* for interaction >0.10; Figure). SAF ($s\beta$ 0.06; 95% CI, –0.01 to 0.12), plasma pentosidine ($s\beta$ 0.05; 95% CI, –0.01 to 0.11), and plasma CML ($s\beta$ 0.06; 95% CI, –0.01 to 0.12) showed positive, nonsignificant associations with aPP (Table S2).

Influence of Previous CVD, Peripheral Neuropathy, and Diabetic Nephropathy on the Associations Between AGE Accumulation and Aortic Stiffening

The inclusion of individuals with previous CVD in our analysis may have influenced the observed associations between measures of AGE accumulation and arterial stiffness. However, exclusion of individuals with previous CVD did not materially change the associations between SAF and plasma AGEs on the one hand and cfPWV and cPP on the other (Figure S1). Furthermore, additional adjustment for PSN and albuminuria, as markers of microvascular disease, did not materially change the associations between SAF and plasma AGEs on the one hand and cfPWV and cPP on the other (Table S3).

Discussion

This study had 3 main findings. First, we found that higher SAF and plasma pentosidine were independently associated with higher cfPWV and cPP. Second, in analyses stratified for glucose metabolism status, we found that the associations between SAF and plasma pentosidine on the one hand and cfPWV on the other were more pronounced in individuals with T2DM. This is the first population-based study that describes an association between SAF and measures of aortic stiffening in individuals with NGM, IGM, and T2DM. Our results are in agreement with previous studies, which demonstrated that skin AGEs are associated with arterial stiffening in type 1 diabetes mellitus,¹⁶ heart disease, and ¹⁰ end-stage renal disease¹¹ and in the elderly.^{12,19} We found relatively small standardized regression coefficients in these associations. In comparison, $s\beta$ s and 95% CIs of the associations between mean arterial pressure and age on the one hand and cfPWV on the other were 0.37 (0.31–0.43) and 0.31 (0.24–0.38), respectively, in our study. However, the fact that these coefficients were statistically significant suggests that the association between the different measures of AGEs and measures of arterial stiffness, albeit small, indeed reflect a true association

Table 1. General Characteristics of the Maastricht Study Participants

Characteristics	Tertiles of Carotid to Femoral Pulse-Wave Velocity (n=820)			
	First Tertile (n=273); (4.8–7.8 m/s)	Second Tertile (n=274); (7.8–9.4 m/s)	Third Tertile (n=273); (9.4–20.2 m/s)	P Value
NGM/IGM/T2DM, %	72/11/17	57/18/25	35/20/45	<0.001
Age, y	55±8	60±8	65±6	<0.001
Sex (number of men/women)	122/151	159/115	165/108	<0.001
Diabetes mellitus duration, y	4 (2–7)	7 (2–11)	8 (5–13)	<0.001
HbA1c, %	5.8±0.7	5.9±0.6	6.3±1.0	<0.001
HbA1c, mmol/mol	40±8	41±7	45±11	<0.001
Smoking, never/former/current, %	37/45/18	28/56/16	29/57/14	0.052
Waist circumference, cm	93±13	97±13	100±13	<0.001
Total-to-HDL cholesterol ratio	4.0±1.2	4.4±1.2	4.2±1.3	0.006
Triglycerides, mmol/L	1.1 (0.8–1.6)	1.2 (0.9–1.8)	1.4 (1.0–2.0)	<0.001
eGFR _{CKD-EPI} , mL/min/1.73 m ²	90±13	84±14	80±15	<0.001
Albuminuria (normo/micro/macro), %	95/4/1	94/5/1	88/11/1	0.008
Peripheral sensory neuropathy, n (%)	9 (4)	16 (8)	40 (22)	<0.001
Hypertension, n (%)	97 (36)	157 (57)	217 (80)	<0.001
Antihypertensive medication, n (%)	74 (27)	108 (39)	141 (52)	<0.001
Lipid-modifying medication, n (%)	68 (25)	92 (34)	136 (50)	<0.001
Diabetes mellitus medication, n (%)	41 (15)	57 (21)	88 (32)	<0.001
History of CVD, n (%)	33 (13)	46 (17)	60 (24)	0.003
SAF, AU	2.55±0.51	2.70±0.50	2.88±0.55	<0.001
Pentosidine, nmol/mmol LYS	0.44 (0.37–0.53)	0.47 (0.38–0.56)	0.49 (0.40–0.61)	<0.001
CML, nmol/mmol LYS	74.8±14.4	74.7±14.7	73.6±15.1	0.586
CEL, nmol/mmol LYS	34.3±10.8	33.2±9.3	34.8±10.6	0.183
cfPWV, m/s	6.98±0.59	8.60±0.47	11.4±1.8	...
MAP, mm Hg	92±8	98±9	103±10	<0.001
Heart rate, bpm	62±8	63±8	65±9	<0.001
Central pulse pressure, mm Hg	38 (33–47)	45 (38–55)	55 (44–68)	<0.001
Ambulatory 24-h PP, mm Hg	41±7	44±8	51±9	<0.001
Ambulatory 24-h MAP, mm Hg	90±7	93±8	96±9	<0.001
Ambulatory 24-h heart rate, bpm	70±8	69±9	71±9	0.014

Data are presented as mean±SD or as median (IQR), unless otherwise indicated. AU indicates arbitrary units; CEL, N(epsilon)-(carboxyethyl)lysine; CML, N(epsilon)-(carboxymethyl)lysine; cfPWV, carotid to femoral pulse-wave velocity; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR_{CKD-EPI}, estimated glomerular filtration rate; HbA1c, glycohemoglobin; HDL, high-density lipoprotein; IGM, impaired glucose metabolism; MAP, mean arterial pressure; NGM, normal glucose metabolism; SAF, skin autofluorescence; SBP, systolic blood pressure; and T2DM, type 2 diabetes mellitus.

between AGE accumulation and aortic stiffening. In fact, the effect size on an association does not necessarily reflect the biological importance of the pathophysiological process. Therefore, these results provide us with more insight into the pathophysiology of arterial stiffening and the possible role of AGEs herein.

AGEs are thought to affect vascular tissue via distinct pathways. First, certain AGEs, for example, pentosidine, are able to form cross-links between extracellular matrix proteins such as collagen in the arterial wall, which may directly result in a decrease in vascular elasticity and an increase in arterial stiffening.^{8,13,30} Second, other AGEs, for example, CEL, are able

to affect cell function via intracellular glycation of proteins, altering the function of these proteins,⁹ for example, leading to the quenching of nitric oxide resulting in increased smooth muscle cell tone, which contributes to arterial stiffening.³¹ Third, some AGEs, for example, CML, are known to bind to the RAGE, inducing receptor-mediated cell activation and low-grade inflammation,^{32,33} which in its turn may promote arterial stiffening via for example, MMPs, endothelial dysfunction that elevates smooth muscle tone, and a reduction of endothelial flow-mediated dilation.³¹ In addition to an association between SAF and measures of aortic stiffening, we found a positive association between plasma pentosidine and aortic stiffening.

Table 2. Associations Between Measures of AGE Accumulation and cfPWV or cPP

AGEs	Model	Carotid to Femoral Pulse-Wave Velocity			Central Pulse Pressure		
		sβ	95% CI	P Value	sβ	95% CI	P Value
SAF	1	0.10	0.03 to 0.17	0.006	0.06	−0.02 to 0.14	0.114
	2	0.11	0.05 to 0.17	0.001	0.07	0.00 to 0.14	0.050
	3	0.10	0.03 to 0.17	0.004	0.08	0.01 to 0.15	0.018
Plasma pentosidine	1	0.08	0.02 to 0.15	0.011	0.09	0.03 to 0.16	0.007
	2	0.08	0.02 to 0.14	0.005	0.09	0.03 to 0.15	0.003
	3	0.10	0.04 to 0.16	0.002	0.07	0.01 to 0.13	0.025
Plasma CML	1	−0.01	−0.07 to 0.06	0.870	0.05	−0.02 to 0.12	0.135
	2	0.00	−0.06 to 0.06	0.928	0.06	0.00 to 0.12	0.062
	3	0.00	−0.06 to 0.07	0.895	0.04	−0.03 to 0.10	0.281
Plasma CEL	1	0.03	−0.04 to 0.09	0.393	−0.02	−0.09 to 0.05	0.561
	2	0.03	−0.03 to 0.08	0.348	−0.02	−0.08 to 0.04	0.556
	3	0.01	−0.04 to 0.07	0.643	0.00	−0.06 to 0.06	0.932

Model 1 is adjusted for age, sex, and glucose metabolism status. Model 2 is additionally adjusted for average mean arterial pressure. Model 3 is additionally adjusted for average heart rate, waist circumference, smoking, antihypertensive and lipid-modifying and diabetes medication use, eGFR, total-to-HDL cholesterol ratio, triglycerides, and a history of cardiovascular disease. There were 740 individuals (414 with NGM, 122 with IGM, and 203 with T2DM) included in the analyses between SAF and cfPWV, 752 individuals (417 with NGM, 122 with IGM, and 208 with T2DM) in the analyses between plasma AGEs and cfPWV, 726 individuals (401 with NGM, 127 with IGM, and 208 with T2DM) included in the analyses between SAF and cPP and 739 (405 with NGM, 127 with IGM, and 207 with T2DM) individuals in the analyses between plasma AGEs and cPP. Standardized β , the standardized regression coefficient obtained with linear regression analyses, indicates the change in cfPWV or cPP (in SD) per 1 SD higher SAF or level of plasma advanced glycation endproducts, that is, plasma pentosidine, CML and CEL. AGE indicates advanced glycation end product; CEL, N(epsilon)-(carboxyethyl)lysine; cfPWV, carotid to femoral pulse-wave velocity; CI indicates confidence interval; CML, N(epsilon)-(carboxymethyl)lysine; cPP, central pulse pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IGM, impaired glucose metabolism; NGM, normal glucose metabolism; SAF, skin autofluorescence; and T2DM, type 2 diabetes mellitus

One previous study found no association between serum pentosidine and heart-brachial PWV or brachial-ankle PWV after adjustment for renal function.¹⁵ However, this was based on a small, case-control study. Next, we found no association between plasma CML and CEL and cfPWV or cPP. This is in contrast with other studies that demonstrated an association between the plasma AGEs, CML, and CEL, and arterial stiffening in other populations.^{13,14,17–19} In the case of CML, it has recently been described that the trapping of CML by the RAGE in adipose tissue causes a decrease in AGE plasma levels in individuals with T2DM.³⁴ Therefore, plasma CML may not be a good reflection of CML accumulation in tissues in individuals with T2DM. This may explain why we did not find an association between plasma CML and aortic stiffening in our population. We do not have a clear explanation why we found no association between CEL and aortic stiffening, whereas others, in different populations, did. Because we only found an association between plasma pentosidine and cfPWV and cPP, this could indicate that cross-linking of AGEs, and not, or to a lesser extent intracellular glycation or RAGE activation, is the predominant pathway through which AGEs lead to aortic stiffening in T2DM. However, we cannot exclude the possibility that plasma pentosidine is simply a better reflection of the detrimental effects of AGEs on the vessel wall in general. Taken together, the results of our study combined with previous research, support the hypothesis that AGE accumulation, and in particular AGE cross-linking, may play a role in the development of arterial stiffening in individuals with NGM, IGM, and T2DM. We found nonsignificant positive associations

between SAF, plasma pentosidine, and CML on the one hand and aPP on the other. These results may be explained by the fact that cfPWV, as the gold-standard measurement of aortic stiffening,²⁸ and cPP are more precise markers of arterial stiffening compared with aPP. The associations between both SAF and pentosidine on the one hand and cfPWV on the other were more pronounced in individuals with T2DM. Additionally, the association between SAF and cfPWV was also more pronounced in individuals with IGM. This could be caused by the fact that in individuals with higher AGE levels, there is not only more cross-linking but also more RAGE activation with subsequent low-grade inflammation, and more intracellular glycation. As discussed above, these mechanisms could both lead to a further increase in arterial stiffening. Additionally, we cannot exclude the possibility that for individuals with NGM, having less variation in AGE accumulation and arterial stiffening compared with individuals with T2DM, it is more difficult to find an association between the 2. We excluded the possibility that the inclusion of individuals with previous CVD or microvascular disease influenced our findings, by repeating analyses in individuals without CVD only and by adjusting for markers of microvascular disease, after which we found similar results. When we additionally adjust the association between SAF and plasma AGEs on the one hand and cfPWV on the other for fasting glucose level, we find smaller sβ (sβ 0.06; 95% CI, −0.01 to 0.14 for SAF, and sβ 0.05; 95% CI, −0.02 to 0.11 for pentosidine), and associations were no longer significant. This could mean that part of the association between AGE measurements and arterial stiffening is explained by a difference in glucose




Figure. Associations between measures of advanced glycation end product (AGE) accumulation and carotid to femoral pulse-wave velocity (cfPWV) or central pulse pressure (cPP) in individuals with normal glucose metabolism (NGM), impaired glucose metabolism (IGM), and type 2 diabetes mellitus (T2DM). Data are presented as standardized β ($s\beta$) and 95% confidence interval. $s\beta$ is the standardized regression coefficient obtained with linear regression analyses, which indicates the change in cfPWV or cPP in SD per 1 SD higher skin autofluorescence (SAF), level of plasma pentosidine, plasma N ϵ -(carboxymethyl)lysine (CML) or plasma N ϵ -(carboxyethyl)lysine (CEL) in the total population, individuals with normal glucose metabolism (NGM), impaired glucose metabolism (IGM), or T2DM. The presented $s\beta$ s are adjusted for age and sex, average mean arterial pressure and heart rate, waist circumference, smoking, antihypertensive and lipid-modifying and diabetes mellitus medication use, estimated glomerular filtration rate, total-to-high-density lipoprotein cholesterol ratio, triglycerides, and a history of cardiovascular disease. The displayed P values indicate the significance of interaction of glucose metabolism status in these associations.

levels between GMS groups. Another explanation for these findings is that glucose is a marker in the same pathway as SAF and AGEs, which causes the regression coefficient to diminish. For this study, we used both SAF, an estimate of skin AGEs, and protein-bound AGEs in plasma to serve as a reflection of tissue AGEs. SAF is thought to reflect AGE accumulation and AGE cross-linking in the extracellular matrix of the vessel wall more accurately than plasma proteins, as plasma AGE levels are determined to a large extent by the half-life of plasma proteins, which is significantly shorter than the half-life of long-lived proteins in the skin and in vascular tissue.³⁵ The fact that we found an association between SAF and aortic stiffening and

not between plasma CML or CEL and aortic stiffening further supports this hypothesis, at least for plasma CML and CEL. As AGE accumulation may be involved in the development of arterial stiffening and CVD in individuals with T2DM, AGE-lowering therapies may decrease the risk of CVD in individuals with T2DM. One of the well-studied, potential, anti-AGE therapies is the cross-link breaker alagebrium (ALT-711). Indeed, it has been shown that alagebrium is able to reduce large artery stiffening in animal models.³⁶ One double-blind randomized controlled trial correspondingly showed a decrease in pulse pressure and cfPWV in individuals who received alagebrium.³⁷ However, another double-blind randomized controlled trial

showed no treatment effects on cardiac function and exercise tolerance.³⁸

Strengths of this study include the large and well-characterized samples, the assessment of aortic stiffening and the use of state-of-the-art techniques to measure multiple markers of glycation end products. Limitations of the study include, first, this cross-sectional design of the study; therefore, we cannot draw any conclusions about causality in the association between AGE accumulation and aortic stiffening. Second, by stratifying for glucose metabolism status, we performed analyses in a smaller number of individuals, especially in the IGM group, which diminishes the power to detect an association. Third, as stated previously, we do not know whether and to what extent the different plasma AGEs reflect specific pathophysiological pathways, that is, cross-linking, intracellular protein glycation, or RAGE activation, or are merely a reflection of AGE formation and vascular damage in general.

Perspectives

Arterial stiffening increases the risk of cardiovascular disease, especially among individuals with type 2 diabetes mellitus. We demonstrate that higher levels of SAF, plasma pentosidine, and plasma CML were associated with more aortic stiffening and that associations for cfPWV were more pronounced in individuals with T2DM. These results support the hypothesis that AGE accumulation is involved in arterial stiffening in general, and, moreover, the accelerated arterial stiffening in individuals with T2DM. Prospective studies are needed. Assuming causality between AGEs and arterial stiffness, interference in the pathways of AGE accumulation might influence the development and progression of arterial stiffening, in particular in individuals with T2DM. Therefore, more large, specific, and well-designed studies are needed to elucidate their potential effect in humans, in particular individuals with T2DM.

Acknowledgments

We would like to thank all the investigators and participants who kindly participated in this study. M.G.A. van Eupen and M.T. Schram participated in the data collection, in the conception and design of this study, and in analysis and interpretation of the data; drafted the article; and provided final approval of the version to be published. T.T. van Sloten, J. Scheijen, S.J.S. Sep, C.J. van der Kallen, P.C. Dagnelie, A. Koster, N. Schaper, R.M.A. Henry, A.A. Kroon participated in the data collection, conception, and design of The Maastricht Study and provided final approval of the version to be published. A.J. Smit participated in the interpretation of the data and provided final approval of the version to be published. C.G. Schalkwijk participated in the conception and design of this study; was responsible for the measurements of AGE accumulation, analysis, and interpretation of the data; drafted the article; and provided final approval of the version to be published. C.D.A. Stehouwer participated in the conception and design of this study, analysis, and interpretation of the data and in the revision of the article for important intellectual content and provided final approval of the version to be published.

Sources of Funding

This research was performed within the framework of CTMM, the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDICt (grant 01C-104), and supported by the Dutch Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation. The Maastricht Study was supported by the European Regional Development Fund as part of OP-ZUID, the province of

Limburg, the department of Economic Affairs of the Netherlands (grant 31O.041), Stichting the Weijerhorst, the Pearl String Initiative Diabetes, the Cardiovascular Center Maastricht, Cardiovascular Research Institute Maastricht, School for Nutrition, Toxicology and Metabolism (NUTRIM), Stichting Annadal, Health Foundation Limburg, and by unrestricted grants from Janssen, Novo Nordisk, and Sanofi. We would like to thank all the investigators and participants who kindly participated in this study.

Disclosures

A.J. Smit is founder and shareholder of Diagnostix Technologies BV, The Netherlands, manufacturing AGE readers (<http://www.diag-noptics.com>). The other authors report no conflicts.

References

1. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010;55:1318–1327. doi: 10.1016/j.jacc.2009.10.061.
2. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. *Hypertension*. 2001;37:1236–1241.
3. Sutton-Tyrrell K, Najjar SS, Bouillon RM, Venkatchalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, Pahor M, Bauer D, Newman A; Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. *Circulation*. 2005;111:3384–3390. doi: 10.1161/CIRCULATIONAHA.104.483628.
4. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. *Circulation*. 2006;113:664–670. doi: 10.1161/CIRCULATIONAHA.105.579342.
5. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? *Circulation*. 2002;106:2085–2090.
6. Cameron JD, Bulpitt CJ, Pinto ES, Rajkumar C. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. *Diabetes Care*. 2003;26:2133–2138.
7. Schram MT, Kostense PJ, Van Dijk RA, Dekker JM, Nijpels G, Bouter LM, Heine RJ, Stehouwer CD. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. *J Hypertens*. 2002;20:1743–1751.
8. Sell DR, Monnier VM. Molecular basis of arterial stiffening: role of glycation - a mini-review. *Gerontology*. 2012;58:227–237. doi: 10.1159/000334668.
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001;414:813–820. doi: 10.1038/414813a.
10. Hofmann B, Adam AC, Jacobs K, Riemer M, Erbs C, Bushnaq H, Simm A, Silber RE, Santos AN. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? *Exp Gerontol*. 2013;48:38–44. doi: 10.1016/j.exger.2012.04.011.
11. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. *Metabolism*. 2008;57:1452–1457. doi: 10.1016/j.metabol.2008.05.016.
12. Wafar G, Souliis G, Tartagni E, Kearney-Schwartz A, Borghi C, Salvi P, Benetos A. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. *Diabetes Metab*. 2012;38:413–419. doi: 10.1016/j.diabet.2012.04.004.
13. McNulty M, Mahmud A, Feely J. Advanced glycation end-products and arterial stiffness in hypertension. *Am J Hypertens*. 2007;20:242–247. doi: 10.1016/j.amjhyper.2006.08.009.
14. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. *Am J Hypertens*. 2009;22:74–79. doi: 10.1038/ajh.2008.320.
15. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. *Metabolism*. 2005;54:345–350. doi: 10.1016/j.metabol.2004.09.014.

16. Monnier VM, Vishwanath V, Frank KE, Elmetts CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. *N Engl J Med*. 1986;314:403–408. doi: 10.1056/NEJM198602133140702.
17. Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD; EURODIAB Prospective Complications Study Group. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. *Hypertension*. 2005;46:232–237. doi: 10.1161/01.HYP.0000164574.60279.ba.
18. Sourris KC, Lyons JG, Dougherty SL, Chand V, Straznicki NE, Schlaich MP, Grima MT, Cooper ME, Kingwell BA, de Courten MP, Forbes JM, de Courten B. Plasma advanced glycation end products (ages) and nf-kappab activity are independent determinants of diastolic and pulse pressure. *Clin Chem Lab Med*. 2013;1–10.
19. Semba RD, Sun K, Schwartz AV, Varadhan R, Harris TB, Satterfield S, Garcia M, Ferrucci L, Newman AB; Health ABC Study. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults. *J Hypertens*. 2015;33:797–803; discussion 803. doi: 10.1097/HJH.0000000000000460.
20. Llauroadé G, Ceperuelo-Mallafre V, Vilardell C, Simó R, Gil P, Cano A, Vendrell J, González-Clemente JM. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes. *J Endocrinol*. 2014;221:405–413. doi: 10.1530/JOE-13-0407.
21. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. *Diabetologia*. 2004;47:1324–1330. doi: 10.1007/s00125-004-1451-2.
22. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM, Stehouwer CD. The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol*. 2014;29:439–451. doi: 10.1007/s10654-014-9889-0.
23. Koetsier M, Nur E, Chunmao H, Lutgers HL, Links TP, Smit AJ, Rakhorst G, Graaff R. Skin color independent assessment of aging using skin auto-fluorescence. *Opt Express*. 2010;18:14416–14429.
24. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. *J Chromatogr B Anal Technol Biomed Life Sci*. 2009;877:610–614. doi: 10.1016/j.jchromb.2009.01.022.
25. Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG. Plasma levels of advanced glycation endproducts Ne-(carboxymethyl)lysine, Ne-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. *J Clin Endocrinol Metab*. 2013;98:E1369–E1373. doi: 10.1210/jc.2013-1068.
26. van Sloten TT, Czernichow S, Houben AJ, Protogerou AD, Henry RM, Muris DM, Schram MT, Sep SJ, Dagnelie PC, van der Kallen CJ, Schaper NC, Blacher J, Herberg S, Levy BI, Stehouwer CD. Association Between Arterial Stiffness and Skin Microvascular Function: The SUVIMAX2 Study and The Maastricht Study. *Am J Hypertens*. 2015;28:868–876. doi: 10.1093/ajh/hpu246.
27. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, Filipovsky J, Huybrechts S, Mattace-Raso FU, Protogerou AD, Schillaci G, Segers P, Vermeersch S, Weber T; Artery Society; European Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J Hypertens*. 2012;30:445–448. doi: 10.1097/HJH.0b013e32834fa8b0.
28. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006;27:2588–2605. doi: 10.1093/eurheartj/ehl254.
29. (WHO) WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a who/idf consultation. Geneva, Switzerland: World Health Organization (WHO); 2006.
30. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. *J Hypertens*. 2003;21:3–12. doi: 10.1097/01.hjh.0000042892.24999.92.
31. Ziemann SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. *Arterioscler Thromb Vasc Biol*. 2005;25:932–943. doi: 10.1161/01.ATV.0000160548.78317.29.
32. Basta G, Lazzarini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. *Circulation*. 2002;105:816–822.
33. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. *Ann NY Acad Sci*. 2005;1043:676–680. doi: 10.1196/annals.1333.077.
34. Gaens KH, Stehouwer CD, Schalkwijk CG. Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. *Curr Opin Lipidol*. 2013;24:4–11. doi: 10.1097/MOL.0b013e32835aea13.
35. Smit AJ, Hartog JW, Voors AA, van Veldhuisen DJ. Advanced glycation endproducts in chronic heart failure. *Ann NY Acad Sci*. 2008;1126:225–230. doi: 10.1196/annals.1433.038.
36. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. *Diabetes Obes Metab*. 2013;15:677–689. doi: 10.1111/dom.12058.
37. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. *Circulation*. 2001;104:1464–1470.
38. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA; BENEFICIAL investigators. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. *Eur J Heart Fail*. 2011;13:899–908. doi: 10.1093/eurjhf/hfr067.

Novelty and Significance

What Is New?

- This study demonstrates in a population-based setting that higher levels of advanced glycation end products (AGEs), as measured with state-of-the-art techniques, were associated with more aortic stiffening and that this association was more pronounced in individuals with type 2 diabetes mellitus.

What Is Relevant?

- Assuming causality between AGEs and arterial stiffening, interference in AGE accumulation may influence the development and progression of arterial stiffening, in particular in individuals with type 2 diabetes mellitus.

Summary

AGEs were associated with more aortic stiffening. These data argued in favor of studying AGE-lowering therapies to decrease arterial stiffening and the risk of cardiovascular disease.

Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study

Marcelle G.A. van Eupen, Miranda T. Schram, Thomas T. van Sloten, Jean Scheijen, Simone J.S. Sep, Carla J. van der Kallen, Pieter C. Dagnelie, Annemarie Koster, Nicolaas Schaper, Ronald M.A. Henry, Abraham A. Kroon, Andries J. Smit, Coen D.A. Stehouwer and Casper G. Schalkwijk

Hypertension. 2016;68:956-963; originally published online August 22, 2016;
doi: 10.1161/HYPERTENSIONAHA.116.07446

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/68/4/956>

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2016/08/22/HYPERTENSIONAHA.116.07446.DC1>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Hypertension* is online at:
<http://hyper.ahajournals.org/subscriptions/>

ONLINE SUPPLEMENT

Skin autofluorescence and pentosidine are associated with arterial stiffness:

The Maastricht Study

Marcelle GA van Eupen^{1,4}, Miranda T Schram^{1,4}, Thomas T van Sloten^{1,4}, Jean Scheijen^{1,4}, Simone JS Sep^{1,4}, Carla J van der Kallen^{1,4}, Pieter C Dagnelie^{2,4,5}, Annemarie Koster^{3,5}, Nicolaas Schaper^{1,4,5}, Ronald MA Henry^{1,4}, Abraham A Kroon^{1,4}, Andries J Smit⁶, Coen DA Stehouwer^{1,4,5}, Casper G Schalkwijk^{1,4}

¹ *Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, the Netherlands*

² *Department of Epidemiology, Maastricht University, Maastricht, the Netherlands*

³ *Department of Social Medicine, Maastricht University, Maastricht, the Netherlands*

⁴ *Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands*

⁵ *School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, the Netherlands*

⁶ *Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, University of Groningen, the Netherlands.*

Short title: Advanced Glycation Endproducts and Arterial stiffness

Total number of supplementary figures and tables: 4

Corresponding Author:

Prof. dr. Casper G. Schalkwijk

Maastricht University Medical Center

Department of Internal Medicine

Universiteitssingel 50, 6200 MD

Maastricht, the Netherlands

Telephone: +31 (0)43 3871751

Fax: +31 (0)43 3875006

Email: c.schalkwijk@maastrichtuniversity.nl

Supplementary methods

24-hour ambulatory blood pressure

Ambulatory blood pressure was measured with ambulatory 24-hour BP monitoring (WatchBP O3, Microlife AG, Switzerland). Cuffs were applied to the participants' nondominant arm. Measurements were programmed for every 15 minutes during daytime (08.00–23.00 hours) and every 30 minutes during the night (23.00–08.00 hours), for a total of 24 hours. As quality criteria, mean 24-hour blood pressure measurements were only calculated if more than 14 valid measurements at daytime and more than 7 valid measurements at night were available, based on recommendations of the British Hypertension Society¹. Mean 24-hour ambulatory pulse pressure (aPP, defined as aSBP-aDBP), 24-hour ambulatory heart rate, and 24-hour ambulatory mean arterial pressure (MAP, defined as aDBP + (0.412 x aPP))² were calculated based on hourly averages³. Data on aPP was available for 774 individuals. Missing data were predominantly caused by device non-availability or technical problems.

Measures of peripheral neuropathy and diabetic nephropathy

Vibration perception threshold (VPT) was measured as a marker of peripheral neuropathy. VPT was assessed using a hand-held neurothesiometer (Horwell Scientific Laboratory Supplies, Nottingham, UK). After a test procedure on the participant's elbow, VPT was tested three times at the distal phalanx of the hallux of the right and left foot. The minimum VPT at which the subject was aware of vibration sensation was recorded to the nearest 0.5 V, starting from 0.0 V with stimulation up to 50.0 V. The mean of the three measurements for the least sensitive foot was used in further analyses^{4,5}. Peripheral sensory neuropathy (PSN) was defined as VPT ≥ 25 V (2). To assess urinary albumin excretion, participants were requested to collect two 24-hour urine collections. Urinary albumin concentration was measured with a standard immunoturbidimetric assay by an automatic analyser (Beckman Synchron LX20, Beckman Coulter Inc., Brea, USA) and multiplied by collection volume to obtain the 24-hour urinary albumin excretion. Urinary albumin concentration below the detection limit of the assay (2 mg/l), the urinary albumin concentration was set at 1.5 mg/l before multiplying by collection volume. Only urine collections with a collection time between 20 and 28 hours were considered valid. If needed, urinary albumin excretion was extrapolated to a 24-hours' excretion. Microalbuminuria was defined as a urinary albumin excretion of 30-300 mg per 24 hours whereas macroalbuminuria was defined as a urinary albumin excretion of ≥ 300 mg per 24 hours⁶. These definitions were preferably based on the average of two (90%) 24-hour urine collections.

Covariates

As described previously⁷, fasting venous blood samples were used to assess total cholesterol, LDL and HDL cholesterol, triglycerides, creatinine and HbA1c. Serum total cholesterol, HDL cholesterol, triglycerides, albumin and serum and urine creatinine and uric acid levels were measured with standard (enzymatic and/or colorimetric) methods by an automatic analyzer (Beckman Synchron LX20, Beckman Coulter Inc., Brea, USA). LDL cholesterol was calculated according to the Friedewald formula⁸. Serum creatinine was measured with a Jaffé method traceable to isotope dilution mass spectrometry (Beckman Synchron LX20, Beckman Coulter Inc., Brea, USA). Glomerular filtration rate (eGFR) was estimated using the CKD-EPI (Chronic

Kidney Disease Epidemiology Collaboration) equation based on serum creatinine⁹. HbA1c was measured with ion-exchange high performance liquid chromatography (HPLC) (Variant tm II, Bio-Rad, Hercules, California, USA). Urinary albumin was measured with a immunoturbidimetric assay (Cobas c systems, Roche diagnostics, Mannheim, Germany). Waist circumference was measured in duplicate midway between the lower rib margin and the iliac crest at the end of expiration, to the nearest 0.5 cm, with a flexible plastic tape measure (Seca, Hamburg, Germany). Participants were requested to bring all the medication they used at the time of measurement or a list from their pharmacists to the research center. During a medication interview generic name, dose and frequency, and additional over-the-counter (OTC) medication use were registered by trained staff. All participants received extensive web-based questionnaires. Duration of diabetes was assessed by using the year of diagnosis reported in the questionnaire. Smoking status (never, former, current) was based on smoking cigarettes, cigars and/or pipe tobacco. History of cardiovascular disease was assessed with a modified version of the Rose Questionnaire for the diagnosis of ischemic heart pain and intermittent claudication¹⁰ and defined as self-reported myocardial infarction, and/or cerebrovascular infarction or hemorrhage, and/or percutaneous artery angioplasty of, or vascular surgery on, the coronary arteries, abdominal arteries, peripheral arteries or carotid arteries. Office blood pressure was determined three times on the right arm after a 10-minute rest period, using a non-invasive blood pressure monitor (Omron 705IT, Japan). Hypertension was defined as office systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 and/or the use of antihypertensive medication.

References

1. O'Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, de Swiet M, Mee F. Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the british hypertension society. *BMJ*. 2000;320:1128-1134.
2. Meaney E, Alva F, Moguel R, Meaney A, Alva J, Webel R. Formula and nomogram for the sphygmomanometric calculation of the mean arterial pressure. *Heart*. 2000;84:64.
3. Mancia G, Fagard R, Narkiewicz K et al. 2013 esh/esc guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). *European Heart Journal*. 2013;34:2159-2219.
4. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. *Diabetes Care*. 2004;27:1458-1486.
5. Karvestedt L, Martensson E, Grill V, Eloffsson S, von Wendt G, Hamsten A, Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy: Results from a population-based study of type 2 diabetic patients in sweden. *Diabetes Care*. 2009;32:317-322.
6. K/doi clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39:S1-266
7. Schram MT, Sep SJ, van der Kallen CJ, Dagnelie PC, Koster A, Schaper N, Henry RM, Stehouwer CD. The maastricht study: An extensive phenotyping

- study on determinants of type 2 diabetes, its complications and its comorbidities. *Eur J Epidemiol.* 2014;29:439-451.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:499-502.
 9. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604-612.
 10. Leng GC, Fowkes FG. The edinburgh claudication questionnaire: An improved version of the who/rose questionnaire for use in epidemiological surveys. *J Clin Epidemiol.* 1992;45:1101-1109.

Supplementary Table S1. General characteristics of the Maastricht Study participants by glucose metabolism status.

Characteristics	Glucose metabolism status (n=862)			p-value
	NGM (n=469)	IGM (n=140)	T2DM (n=253)	
NGM/IGM/T2DM (%)	-	-	-	-
Age (years)	57 ± 9	62 ± 8	64 ± 7	<0.001
Sex (number of males/females)	213/256	83/57	176/77	<0.001
Diabetes duration (y)	-	-	7 [3-11]	-
HbA1c (%)	5.6 ± 0.3	5.9 ± 0.4	6.9 ± 0.9	<0.001
HbA1c (mmol/mol)	38 ± 4	41 ± 4	52 ± 10	<0.001
Smoking, never/former/current (%)	36/46/18	28/57/15	22/64/14	<0.001
Waist circumference (cm)	92 ± 11	99 ± 12	106 ± 13	<0.001
Total-to-HDL cholesterol ratio	4.1 ± 1.3	4.4 ± 1.3	4.2 ± 1.2	0.003
Triglycerides (mmol/L)	1.0 [0.8-1.5]	1.4 [1.0-2.1]	1.7 [1.2-2.3]	<0.001
eGFR _{CKD-EPI} (ml/min/1.73m ²)	87 ± 14	82 ± 13	82 ± 16	0.002
Albuminuria (normo/micro/macro) (%)	96/3/1	93/6/1	83/16/1	<0.001
Peripheral sensory neuropathy (n (%))	31 (6)	10 (10)	39 (22)	<0.001
Hypertension (n (%))	189 (40)	92 (66)	219 (87)	<0.001
Anti-hypertensive medication (n (%))	102 (22)	62 (44)	182 (72)	<0.001
Lipid lowering medication (n (%))	76 (16)	51 (36)	191 (76)	<0.001

Diabetes medication (n (%))	0	0	198 (78)	<0.001
History of CVD (n (%))	53 (12)	25 (18)	73 (31)	<0.001
SAF (AU)	2.58 ± 0.49	2.70 ± 0.45	2.95 ± 0.57	<0.001
Pentosidine (nmol/mmol LYS)	0.48 [0.39-0.58]	0.44 [0.38-0.54]	0.45 [0.35-0.57]	0.057
CML (nmol/mmol LYS)	77.2 ± 14.2	72.3 ± 14.1	70.0 ± 14.7	<0.001
CEL (nmol/mmol LYS)	32.8 ± 9.3	34.4 ± 10.5	36.3 ± 11.3	0.002
cfPWV (m/s)	8.37 ± 1.77	9.32 ± 1.96	9.96 ± 2.47	<0.001
MAP (mmHg)	96 ± 11	100 ± 10	99 ± 9	0.001
Heart rate (bpm)	62 ± 8	63 ± 9	66 ± 10	<0.001
Central pulse pressure (mmHg)	43 [35-53]	47 [38-58]	50 [40-64]	<0.001
Ambulatory 24h PP (mmHg)	43 ± 7	47 ± 9	50 ± 10	<0.001
Ambulatory 24h MAP (mmHg)	91 ± 8	95 ± 10	94 ± 8	<0.001
Ambulatory 24h heart rate (bpm)	69 ± 8	70 ± 9	71 ± 10	0.017

Data are presented as mean ± standard deviation (SD) or as median [inter quartile range (IQR)], unless otherwise indicated.

NGM, normal glucose metabolism; IGM, impaired glucose metabolism; T2DM, type 2 diabetes; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; eGFR_{CKD-EPI}, estimated Glomerular Filtration Rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; cfPWV, carotid to femoral pulse wave velocity; MAP, mean arterial pressure; CVD, cardiovascular disease; SAF, skin autofluorescence; CML, N(epsilon)-(carboxymethyl)lysine; CEL, N(epsilon)-(carboxyethyl)lysine.

Supplementary Table S2. Associations between measures of AGE accumulation and aPP

AGEs	Ambulatory			
	24-hour pulse pressure			
	Model	<i>sβ</i>	95% CI	<i>p-value</i>
SAF	1	0.05	-0.02 – 0.13	0.160
	2	0.06	-0.01 – 0.12	0.079
	3	0.06	-0.01 – 0.12	0.085
Plasma pentosidine	1	0.07	0.00 – 0.13	0.043
	2	0.06	0.01 – 0.12	0.033
	3	0.05	-0.01 - 0.11	0.089
Plasma CML	1	0.05	-0.01 – 0.12	0.102
	2	0.07	0.01 – 0.13	0.016
	3	0.06	-0.01 - 0.12	0.078
Plasma CEL	1	0.01	-0.05 – 0.08	0.661
	2	0.01	-0.05 – 0.07	0.771
	3	0.03	-0.03 – 0.09	0.304

Standardized β , the standardized regression coefficient obtained with linear regression analyses, indicates the change in 24-hour ambulatory pulse pressure (aPP) (in SD) per 1 SD higher skin autofluorescence (SAF) or level of plasma advanced glycation endproducts, i.e. plasma pentosidine, CML (N(epsilon)-(carboxymethyl)lysine) and CEL (N(epsilon)-(carboxyethyl)lysine).

Model 1 is adjusted for age, sex and glucose metabolism status. Model 2 is additionally adjusted for average mean arterial pressure*. Model 3 is additionally adjusted for average heart rate*, waist circumference, smoking, antihypertensive, lipid-modifying and diabetes medication use, eGFR, total-to-HDL-cholesterol ratio,

triglycerides and a history of cardiovascular disease.

There were 696 individuals (389 with NGM, 114 with IGM and 193 with T2DM) included in the analyses between SAF and aPP, and 712 individuals (394 with NGM, 119 with IGM and 199 with T2DM) in the analyses between plasma AGEs and aPP.

* In analyses with aPP, average mean arterial pressure and heart rate obtained from 24-hour ambulatory blood pressure measurement were used in Model 2 and 3.

Supplementary Table S3. Associations between measures of AGE accumulation and measures of arterial stiffness with and without additional adjustment for peripheral sensory neuropathy and albuminuria.

AGEs	Model	Carotid to femoral pulse wave velocity			Central pulse pressure		
		<i>sβ</i>	95% <i>CI</i>	<i>p</i> - <i>value</i>	<i>sβ</i>	95% <i>CI</i>	<i>p</i> - <i>value</i>
SAF	1	0.09	0.02 – 0.17	0.017	0.10	0.02 – 0.18	0.015
	2	0.09	0.02 – 0.17	0.017	0.10	0.02 – 0.19	0.013
Plasma pentosidine	1	0.05	-0.02 – 0.13	0.139	0.09	0.02 – 0.17	0.015
	2	0.06	-0.02 – 0.13	0.127	0.09	0.02 – 0.17	0.013
Plasma CML	1	0.01	-0.07 – 0.08	0.827	0.05	-0.03 – 0.12	0.244
	2	0.01	-0.06 – 0.08	0.827	0.05	-0.03 – 0.12	0.237
Plasma CEL	1	0.02	-0.04 – 0.09	0.512	0.02	-0.05 – 0.09	0.526
	2	0.02	-0.04 – 0.09	0.498	0.02	-0.05 – 0.09	0.521


Standardized β , the standardized regression coefficient obtained with linear regression analyses, indicates the change in carotid to femoral pulse wave velocity (cfPWV) or central pulse pressure (cPP) (in SD) per 1 SD higher skin autofluorescence (SAF) or level of plasma advanced glycation endproducts, i.e. plasma pentosidine, CML (N(epsilon)-(carboxymethyl)lysine) and CEL (N(epsilon)-(carboxyethyl)lysine).

Model 1 is adjusted for age, sex and glucose metabolism status, average mean arterial pressure, average heart rate, waist circumference, smoking, antihypertensive and lipid-lowering medication use, eGFR, total-to-HDL-cholesterol ratio, triglycerides and a history of cardiovascular disease. Model 2 is additionally adjusted for peripheral sensory neuropathy (PSN) and albuminuria.

There were 547 individuals included in the analyses between SAF and cfPWV, 555

individuals in the analyses between plasma AGEs and cfPWV, 536 individuals in the analyses between SAF and cPP, and 545 individuals in the analyses between plasma AGEs and cPP.

Supplementary Figure S1. Associations between measures of AGE accumulation and measures of arterial stiffness in the total population and in the population without prior cardiovascular disease.



Data are presented as standardized β (s β) and 95%-confidence interval. s β is the standardized regression coefficient obtained with linear regression analyses, which indicates the change in carotid to femoral pulse wave velocity (cfPWV) or central pulse pressure (cPP) (in SD) per 1 SD higher skin autofluorescence (SAF) or level of plasma pentosidine.

The presented s β 's are adjusted for age, sex, glucose metabolism status, average mean arterial pressure and heart rate, waist circumference, smoking, antihypertensive and lipid-modifying medication use, eGFR, total-to-HDL-cholesterol ratio and triglycerides.

For the analyses in the total population, there were 740 individuals included in the

analyses between SAF and cfPWV, 752 individuals in the analyses between plasma AGEs and cfPWV, 726 individuals in the analyses between SAF and cPP and 739 in the analyses between plasma AGEs and cPP. For the analyses in the population without prior CVD, there were 611 individuals included in the analyses between SAF and cfPWV, 622 individuals in the analyses between plasma AGEs and cfPWV, 599 individuals in the analyses between SAF and cPP, and 611 individuals in the analyses between plasma AGEs and cPP.